
Opinion|Videos|November 12, 2024
GALAXY 24-Month Data from ESMO 2024: MRD Status and ctDNA Clearance Key in CRC
Panelists discuss how the 24-month data from the GALAXY study presented at the European Society for Medical Oncology (ESMO) 2024 meeting underscore the importance of minimal residual disease (MRD) status and circulating tumor DNA (ctDNA) clearance as key prognostic and predictive factors in colorectal cancer (CRC) management.
Advertisement
Episodes in this series

Advertisement
Related to this article

Chinmay Jani, MD, discusses ASCO 2026 data on lung cancer trends in younger adults and why this group has been overlooked.

Data from the OrigAMI-4 trial support the accelerated approval of amivantamab and hyaluronidase-lpuj for this HNSCC population.

Bhanu Prasad Venkatesulu, MBBS, MD, discussed why fewer radiation oncologists offer prostate brachytherapy and the patients for whom he still recommends it.

Chinmay Jani, MD, explains how air pollution and asbestos contribute to lung cancer deaths beyond tobacco.

Claudine Isaacs, MD, and community oncologists weigh ASCENT-03 and ASCENT-04 data, crossover, and toxicity management with sacituzumab govitecan in TNBC.

The FDA assigned an April 9, 2027, target action date to resubmitted applications for rivoceranib plus camrelizumab in unresectable or metastatic hepatocellular carcinoma.

Adam C. Olson, MD, MSc-GH, discussed letting patients choose between modalities with comparably strong evidence, and the data that shaped his approach.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves SC Amivantamab for Recurrent/Metastatic HNSCC
2
FDA Sets PDUFA Date for Rivoceranib/Camrelizumab Resubmission After Third CRL in Unresectable HCC
3
Sacituzumab Govitecan Efficacy, Safety Debated in First-Line Metastatic TNBC
4
Air Pollution Emerges as Second Leading Risk Factor for Lung Cancer Deaths
5

